Diligence memo · auto-generated · as of July 2, 2026
Aeterna Zentaris Inc.
Aeterna Zentaris Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Aeterna Zentaris Inc. operates in Pharmaceuticals, based in SUMMERVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aeterna Zentaris Inc. has raised $9.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2019-09-20.
Most recent recorded round closed around 2020-02-19.
Valuation (modeled)modeled
Provath models Aeterna Zentaris Inc. at approximately $139M (range $5.2M–$758M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.91× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 6.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 52% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 61% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.